Abivax SA
PAR:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Guangzhou Zhujiang Brewery Co Ltd
SZSE:002461
|
CN |
Abivax SA
Common Stock
Abivax SA
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Common Stock
€640k
|
CAGR 3-Years
47%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Common Stock
€25.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Common Stock
€12.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Inventiva SA
PAR:IVA
|
Common Stock
€1.4m
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Common Stock
$15.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
22%
|
CAGR 10-Years
23%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Common Stock
€3.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
11%
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Common Stock?
Common Stock
640k
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's Common Stock amounts to 640k EUR.
What is Abivax SA's Common Stock growth rate?
Common Stock CAGR 5Y
45%
Over the last year, the Common Stock growth was 2%. The average annual Common Stock growth rates for Abivax SA have been 47% over the past three years , 45% over the past five years .
